Quality, preclinical and clinical aspects of gene therapy medicinal products

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CAT/80183/2014
Effective from01/03/2018
KeywordsGene therapy medicinal products, advanced therapy medicinal products (ATMPs), quality, non-clinical, clinical
DescriptionThis guideline is a revision of the Note for Guidance on the Quality, Preclinical and Clinical aspects of gene transfer medicinal products (CPMP/BWP/3088/99), which was published in 2001. It defines scientific principles and provides guidance for the development and evaluation of Gene Therapy Medicinal Products (GTMPs) intended for use in humans and presented for Marketing Authorisation Application (MAA). Its focus is on the quality, safety and efficacy requirements of GTMPs.

Document history

Revision 1
Current version

Adopted guideline

Overview of comments

Draft guideline

Concept paper

Published: 13/07/2018

Published: 13/07/2018

Published: 20/05/2015

Published: 12/01/2010

First versionAdopted guidelineIn operation: 01/10/2001–present

Related content

How helpful is this page?

Average rating:

 Based on 40 ratings

Add your rating:

See all ratings
7 ratings
7 ratings
7 ratings
7 ratings
12 ratings

Tell us more